Laurus Labs Ltd. · NSE:LAURUSLABS
Laurus Labs — Q4 FY21 Earnings Presentation
25 slides from Laurus Labs's earnings presentation, Apr 29, 2021
Slide 1: Exchange filing cover letter for investor presentation
Laurus Labs Limited Corporate Office 2"d Floor, Serene Chambers, Road No. 7 Banjara Hills, Hyderabad - 50003~. Telangana, India T +91 ~ 0 66 59 ~333, 3980 ~333, 23~2 0500 I 501 LAURUS Labs F +91 ~0 66 59 ~320 I 3980 ~320 Knowledge . Innovation . Excellence April29, 2021 To To The Corporate Relations
Slide 2: Q4 & FY21 Investor Presentation
LAURUS LABS LIMITED Q4 & FY21 INVESTOR PRESENTATION April 29, 2021 BSE: 540222 NSE : LAURUSLABS
Slide 3: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 4: Consistent Quarterly Performance
₹ Cr Consistent Quarterly Performance Revenue (YoY Gr 70 %) EBITDA (YoY Gr 176%) MARGIN % 33% 34% 34% 1,412 29% 1,289 1,139 23% 20% 21% 974 839 16% 712 730 477 433 551 379 284 193 140 150 87 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 FY20 FY20 FY20 FY20 FY21 FY21 FY21 FY21 FY20 FY20 FY20 FY20 F
Slide 5: Business Snapshot
Business Snapshot Division Generic API • Generic FDF • Synthesis (CDMO) • Bio Overview • Development, manufacture and sale of • Developing and manufacturing oral solid • Contract development and manufacturing • Bio - Manufacturing APIs and Advanced Intermediates formulations for LMIC, North America
Slide 6: Segmental Revenue Breakup
Segmental Revenue Breakup ₹ Cr Generics API Generics FDF Synthesis 452 430 430 176 797 148 731 352 127 571 267 116 522 100 424 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 FY20 FY21 FY21 FY21 FY21 FY20 FY21 FY21 FY21 FY21 FY20 FY21 FY21 FY21 FY21 • Generic API division showcased a robust growth of 6
Slide 7: Generic API Division
Generic API Division ₹ Cr Anti Viral API Onco API Other API 568 569 166 86 135 379 64 62 336 59 106 99 51 92 273 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Strong demand in 1st line ARV API Order book position is robust
Slide 8: Generic FDF Division
Generic FDF Division ₹ Cr 452 430 430 352 267 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 FDF Business delivered robust growth for the quarter. This is driven by continued strong demand in ARV segment of LMIC region and portfolio expansion in developed markets Overall FDF revenue for FY 21 grew by 1
Slide 9: Synthesis (CDMO) Division
Synthesis (CDMO) Division ₹ Cr 176 148 127 116 100 Q4 FY20 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Synthesis business delivered robust growth for the quarter Total Number of Active Projects in the CDMO division stood at the end of FY21 was 50 (vs 40 in FY20) Multiple Partnership proposals are in colla
Slide 10: 15 years journey so far
15 years journey so far As on As on As on Capabilities * Mar-11 Mar-16 Mar-21 Financials (₹ Cr) * (for each period of 5 Yrs) FY 06-FY 11 FY 11-FY 16 FY 16-FY 21 Sources Description of the ARV API API Pharmaceutical Company company Company Company Cash Profit (PAT +Dep) 7 633 2,478 Team Strength 883
Slide 11: 5 year Division wise Revenue Contribution
5 year Division wise Revenue Contribution 2% 7% 9% 10% 3% 13% 8% 8% 8% 29% 35% 6% 9% 8% 10% 14% 11% 11% 11% 82% 7% 5% 77% 74% 66% 39% 38% FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 Anti Viral API Onco API Other API Custom Synthesis Generic FDF 10
Slide 12: Financial Track Record – Trend from FY17 to FY21
Financial Track Record – Trend from FY17 to FY21 ₹ Cr Revenue EBITDA MARGIN % 33% PAT EPS in ₹ 18.3 4,814 23% 21% 20% 16% 1,573 2,832 984 2,292 1,905 2,056 4.2 4.8 3.2 570 1.8 440 442 371 190 255 168 94 FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21 FY 17 FY 18 FY 19 FY 20 FY 21 Capex S
Slide 13: 5 years Return Ratios
5 years Return Ratios Pre Tax Return on Capital Return on Equity(2) (%) Net Debt/EBIDTA (3) (x) Employed(1) (%) 45.1% 40.1% 2.8x 2.2x 1.9x 1.9x 16.5% 17.4% 13.7% 14.1% 15.3% 11.9% 8.2% 0.9x 6.2% FY17 FY 18 FY 19 FY 20 FY 21 FY17 FY 18 FY 19 FY 20 FY 21 FY17 FY 18 FY 19 FY 20 FY 21 Note: Based on con
Slide 14: Manufacturing Facilities at Parawada, Vizag
Manufacturing Facilities at Parawada, Vizag Unit-I • Located at Jawaharlal Nehru Pharma City, Visakhapatnam, India. • API manufacturing facility and includes capacity for ingredients, synthesis and contract manufacturing. • Commenced operations in 2007. • 328 reactors with 1,226 Kilo Liters capacity
Slide 15: Manufacturing Facilities at Atchutapuram, Vizag
Manufacturing Facilities at Atchutapuram, Vizag • Located at APIIC, Atchutapuram, Visakhapatnam, India. (SEZ) Unit-II • FDF and API manufacturing facility • Commenced operations in 2017. • FDF - capacity of 5 bn tablets/capsules per year. Capacity expansion initiated and will be operational by Q1 FY
Slide 16: Quality Focus & Regulatory Audits
Quality Focus & Regulatory Audits No of USFDA Facility Key Agencies Recent Inspection Year audit ( since inception Kilo Lab – USFDA 2016 – EIR received 3 R&D USFDA, WHO – Geneva, ANVISA, 2019 - 20 – EIR Received, Unit 1 COFEPRIS – Mexico and JZAMP 5 and cGMP certification received Slovenia USFDA, WH
Slide 17: Strong R&D Capabilities
Strong R&D Capabilities R&D Centre - Hyd 184 166 160 134 114 85 7.4% 7.1% 5.6% 5.7% 4.8% 3.8% FY16 FY17 FY18 FY 19 FY 20 FY 21 R&D Spent ₹ Cr % of Revenue Current Filings Status Therapy US ANDA Europe Canada Patents Patents ARV 16 4 5 DMFs Filed Granted Anti- Diabetic 3 3 3 Cumulative CVS 3 - 1 Fili
Slide 18: Covid-19 Response
Covid-19 Response Combatting without Compromising on strategic priorities Focused execution on managing manufacturing, supply chain to ensue adequate stock of materials, Business timely supplies and future capacity enhancements (How) Continuity Set up a dedicated team to ensure real-time assessm
Slide 19: Outlook for FY22 & Beyond
Outlook for FY22 & Beyond Healthy Revenue visibility on the Changing business mix to drive Capacity augmentation to result back of robust Order Book growth in better return ratios • Partnership with Global Fund offers higher • Generic FDF segment contributed ~35% • Among top 5 in India in terms of v
Slide 20: Key Milestones
Key Milestones • Crossed INR 40 billion of revenue • Incorporated Laurus Synthesis Pvt. Ltd & acquired assets of an API Unit in Vizag • Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited • Laurus Synthesis Inc USA is merged with Laurus Generics Inc USA. • INR 10 billion FDF S
Slide 21: Board of Directors & Leadership Team
Board of Directors & Leadership Team Executive Directors Name Background Dr Satyanarayana Chava Whole-time Director, Founder and Chief Executive Officer Ravi Kumar V V Whole-time Director and CFO Dr Lakshmana Rao C V Whole-time Director and Head, Quality Non-Executive Directors Name Background
Slide 22: Ownership Structure
Ownership Structure Corporate Structure Laurus Labs Limited All are 100% Subsidiaries except India Laurus Bio* Sriam Laurus *Laurus Laurus Laurus Labs Pvt Ltd. Holdings Ltd. Bio Pvt Ltd. Synthesis Pvt. Ltd Generics SA (PTY) Ltd India UK 79.21% Laurus Laurus Laurus Generics Inc. Generics GmbH. Ingred
Slide 23: Conference Call Details
Conference Call Details Results conference call on Friday April 30, 2021 at 11:00 AM IST Details of the conference call are as follows Location Dial-In Details Conference dial-in Universal Dial-In +91 22 6280 1148 India Local access Number +91 22 7115 8049 Available all over India Singapore 800 101
Slide 24: Contact us
Contact us About Laurus Labs Ltd. Laurus Labs is a leading research driven Pharmaceutical manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology .We are thri
Slide 25: Thank You
Thank You